A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation


This study will evaluate the clinical activity/efficacy of MRTX849 in cohorts of patients having selected solid tumor malignancies with KRAS G12C mutation.

I'm interested

18 Years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
• Unresectable or metastatic disease
• Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
• Adequate organ function
Exclusion Criteria:

• History of intestinal disease or major gastric surgery or inability to swallow oral medications
• Other active cancer

Drug: MRTX849, Drug: Pembrolizumab, Drug: Cetuximab, Drug: Afatinib

Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

KRAS, NSCLC, Colorectal Cancer, Colon Cancer, Metastatic Cancer, Pancreatic Cancer, Adagrasib, STK11 mutation, KRAS G12C, Clinics and Surgery Center (CSC), Phase I Clinic

Manish Patel -
Amit Kulkarni
Phase 1/Phase 2
See this study on